Bukwang Pharm
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more
Bukwang Pharm (003000) - Net Assets
Latest net assets as of September 2025: ₩340.83 Billion KRW
Based on the latest financial reports, Bukwang Pharm (003000) has net assets worth ₩340.83 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩472.99 Billion) and total liabilities (₩132.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩340.83 Billion |
| % of Total Assets | 72.06% |
| Annual Growth Rate | 2.13% |
| 5-Year Change | -9.97% |
| 10-Year Change | 8.44% |
| Growth Volatility | 27.82 |
Bukwang Pharm - Net Assets Trend (2007–2024)
This chart illustrates how Bukwang Pharm's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bukwang Pharm (2007–2024)
The table below shows the annual net assets of Bukwang Pharm from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩244.15 Billion | +4.22% |
| 2023-12-31 | ₩234.26 Billion | -13.82% |
| 2022-12-31 | ₩271.85 Billion | -2.93% |
| 2021-12-31 | ₩280.06 Billion | +3.27% |
| 2020-12-31 | ₩271.19 Billion | -16.94% |
| 2019-12-31 | ₩326.49 Billion | -21.03% |
| 2018-12-31 | ₩413.44 Billion | +95.66% |
| 2017-12-31 | ₩211.30 Billion | -1.55% |
| 2016-12-31 | ₩214.63 Billion | -4.67% |
| 2015-12-31 | ₩225.15 Billion | +7.22% |
| 2014-12-31 | ₩210.00 Billion | +4.44% |
| 2013-12-31 | ₩201.07 Billion | +15.56% |
| 2008-12-31 | ₩174.01 Billion | +1.98% |
| 2007-12-31 | ₩170.63 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bukwang Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16682249305000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩166.82 Billion | 68.46% |
| Other Components | ₩76.85 Billion | 31.54% |
| Total Equity | ₩243.68 Billion | 100.00% |
Bukwang Pharm Competitors by Market Cap
The table below lists competitors of Bukwang Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fujimori Kogyo Co. Ltd
F:FJ3
|
$369.35 Million |
|
Kelsian Group Ltd
AU:KLS
|
$369.42 Million |
|
Jiangsu Jiangnan High Polymer Fiber Co Ltd
SHG:600527
|
$369.42 Million |
|
Archi Indonesia Tbk PT
JK:ARCI
|
$369.45 Million |
|
Jiu Han System Technology Co. Ltd.
TWO:6903
|
$369.21 Million |
|
VIA Technologies Inc
TW:2388
|
$369.19 Million |
|
New East New Materials Co Ltd
SHG:603110
|
$369.16 Million |
|
Shanghai Titan Scientific Co. Ltd. A
SHG:688133
|
$369.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bukwang Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 226,311,356,060 to 243,675,730,040, a change of 17,364,373,980 (7.7%).
- Net loss of 2,641,325,690 reduced equity.
- Other factors increased equity by 20,005,699,670.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-2.64 Billion | -1.08% |
| Other Changes | ₩20.01 Billion | +8.21% |
| Total Change | ₩- | 7.67% |
Book Value vs Market Value Analysis
This analysis compares Bukwang Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩3268.34 | ₩6070.00 | x |
| 2018-12-31 | ₩7324.14 | ₩6070.00 | x |
| 2019-12-31 | ₩4866.00 | ₩6070.00 | x |
| 2020-12-31 | ₩4152.55 | ₩6070.00 | x |
| 2021-12-31 | ₩3938.48 | ₩6070.00 | x |
| 2022-12-31 | ₩3530.51 | ₩6070.00 | x |
| 2023-12-31 | ₩3306.00 | ₩6070.00 | x |
| 2024-12-31 | ₩3268.40 | ₩6070.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bukwang Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.65%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.53x
- Recent ROE (-1.08%) is below the historical average (6.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 19.75% | 21.08% | 0.72x | 1.29x | ₩16.20 Billion |
| 2008 | 18.18% | 19.11% | 0.70x | 1.36x | ₩13.89 Billion |
| 2013 | 9.71% | 14.93% | 0.57x | 1.13x | ₩-575.36 Million |
| 2014 | 11.25% | 16.67% | 0.60x | 1.13x | ₩2.62 Billion |
| 2015 | 11.17% | 17.69% | 0.56x | 1.13x | ₩2.62 Billion |
| 2016 | 7.36% | 11.40% | 0.58x | 1.11x | ₩-5.66 Billion |
| 2017 | 5.25% | 7.36% | 0.64x | 1.12x | ₩-10.04 Billion |
| 2018 | 35.24% | 75.00% | 0.39x | 1.19x | ₩104.33 Billion |
| 2019 | -2.27% | -4.41% | 0.43x | 1.19x | ₩-40.04 Billion |
| 2020 | -2.79% | -4.25% | 0.42x | 1.55x | ₩-33.05 Billion |
| 2021 | -0.34% | -0.50% | 0.46x | 1.47x | ₩-27.88 Billion |
| 2022 | -0.94% | -1.30% | 0.48x | 1.52x | ₩-28.80 Billion |
| 2023 | -13.84% | -24.88% | 0.29x | 1.90x | ₩-53.96 Billion |
| 2024 | -1.08% | -1.65% | 0.43x | 1.53x | ₩-27.01 Billion |
Industry Comparison
This section compares Bukwang Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bukwang Pharm (003000) | ₩340.83 Billion | 19.75% | 0.39x | $369.27 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |